Wonderful to be named as a 2024 finalist in the EIT Health Catapult Competition. From 100s of companies considered ➡️ to 30 semi-finalists ➡️ to the last 6. Wish us luck in the Grand Final in June.
We’re excited to announce that Digistain® has partnered Deloitte to drive adoption across Europe! This collaboration marks a significant step toward making breast cancer risk
We’re thrilled to announce that Digistain® is now available to over 60% of UK private patients, with reimbursement available though Bupa, WPA Health Insurance &
We’re proud to share that our landmark clinical validation study, published earlier this year in Breast Cancer Research and Treatment, has been recognised as one
Supported by:
To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.
Digistain LIMITED, Unit 101, Interchange Business Park, Howard Way, Newport Pagnell, MK16 9PY, United Kingdom
From the UK: 020 3951 9812
Outside the UK: +44 20 3951 9812
e-mail: contact@digistain.co.uk
Copyright © 2010 - 2024. Digistain ® and the Digistain Logo are registered trademarks of Digistain LIMITED. All Rights Reserved.
